HKPMDC
 All     Test   
 
News & Event
HKMPDC to provide PIK3CA hotspot mutation test for the first FDA approved treatment Piqray (alpelisib) for patient with PIK3CA mutation in HR+/HER2 advanced breast cancer using either tissue or blood sample.

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Phone: +852.2986.1213
Fax:+852.2527.7028
E-mail:contact@hk-mpdc.com
27/F., Strand 50, No.50 Bonham Strand, Sheung Wan, Hong Kong
Opening Hours
Mondays to Fridays: 09:00-18:00
Saturdays: 09:00-16:00
Sundays and Public Holidays: Closed

For specimen pickup arrangements, please phone +852.2986.1213


Shipping & Billing Information

HOKLAS accreditation scope

Non-disclosure and Complaints
All data/information generated from within/related to HKMPDC and our customers are treated in strict confidence in accordance with the Personal Data (Privacy) Ordinance of Hong Kong. If you have a complaint, please contact us at the (852) 2986 1213 or email us at contact@hk-mpdc.com. All communications with HKMPDC would be dealt with in strict confidence.

Notice of Privacy Practices
This notice describes how medical information about you may be used and disclosed.
Personal health information or related information released to HKMPDC relating to the services requested may be subjected to re-disclosure by HKMPDC to health care providers, such as doctors, nurses, and others involved in the delivery of the services.
We may also disclose medical information about you to authorised public health or government officials for public health activities as required by law and accreditation body.

Copyright © 2013 香港分子病理檢驗中心 Hong Kong Molecular Pathology Diagnostic Centre Limited (HKMPDC). All Rights Reserved.

Information Updated 1 July, 2023.